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Abstract
Background: Multidrug resistance (MDR) is a major obstacle in cancer treatment and is often the result of 
overexpression of the drug efflux protein, P-glycoprotein (P-gp), as a consequence of hyperactivation of NFκB, AP1 and 
Nrf2 transcription factors. In addition to effluxing chemotherapeutic drugs, P-gp also plays a specific role in blocking 
caspase-dependent apoptotic pathways. One feature that cytotoxic treatments of cancer have in common is activation 
of the transcription factor NFκB, which regulates inflammation, cell survival and P-gp expression and suppresses the 
apoptotic potential of chemotherapeutic agents. As such, NFκB inhibitors may promote apoptosis in cancer cells and 
could be used to overcome resistance to chemotherapeutic agents.
Results: Although the natural withanolide withaferin A and polyphenol quercetin, show comparable inhibition of 
NFκB target genes (involved in inflammation, angiogenesis, cell cycle, metastasis, anti-apoptosis and multidrug 
resistance) in doxorubicin-sensitive K562 and -resistant K562/Adr cells, only withaferin A can overcome attenuated 
caspase activation and apoptosis in K562/Adr cells, whereas quercetin-dependent caspase activation and apoptosis is 
delayed only. Interestingly, although withaferin A and quercetin treatments both decrease intracellular protein levels of 
Bcl2, Bim and P-Bad, only withaferin A decreases protein levels of cytoskeletal tubulin, concomitantly with potent PARP 
cleavage, caspase 3 activation and apoptosis, at least in part via a direct thiol oxidation mechanism.
Conclusions: This demonstrates that different classes of natural NFκB inhibitors can show different chemosensitizing 
effects in P-gp overexpressing cancer cells with impaired caspase activation and attenuated apoptosis.
Background
The cytotoxicity of chemotherapeutic agents is attributed
to apoptosis. One feature that cytotoxic treatments of
cancer have in common is their activation of the tran-
scription factor NFκB, which regulates cell survival, sup-
presses the apoptotic potential of chemotherapeutic
agents and contributes to drug resistance [1]. Acquired
resistance to the effects of chemotherapy has emerged as
a significant impediment to effective cancer therapy. As
such, it is believed that inhibitors of NFκB might promote
apoptosis in cancer cells and can be helpful to overcome
resistance to chemotherapeutic agents.
Nuclear factor kappa B (NFκB) is a family of transcrip-
tion factors that play important roles in regulating cell
differentiation, proliferation, immune response and
blocking apoptosis [2,3]. In mammalian cells, the NFκB/
Rel family consists of five members: RelA (p65), RelB, c-
Rel, p105/p50 (NFκB1), and p100/p52 (NFκB2). Each
family member has a conserved Rel homology domain
specifying DNA binding, protein dimerization, and
nuclear localization. In most cells, NFκB is composed of a
heterodimer of p65 and p50, where the p65 protein is
responsible for the transactivation potential. In unstimu-
lated cells, NFκB is sequestered predominantly in the
cytoplasm in an inactive complex through interaction
with IκB inhibitor proteins. In response to stimulation by
a variety of potent activators, such as tumor necrosis fac-
tor (TNF)-α, interleukin (IL)-1, phorbol ester (PMA) or
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lipopolysaccharide [4] and genotoxic agents (doxorubi-
cin, radiation) [5,6], IκBα is rapidly phosphorylated at two
conserved NH2-terminal serines (Ser-32 and Ser-36) and
degraded through a ubiquitin-dependent proteolysis,
resulting in the release of NFκB, its translocation into the
nucleus and induction of gene transcription. The NFκB
has a role in oncogenesis and regulation of cancer therapy
sensitivity. Overexpression, amplification, and rearrange-
ments of different genes related to NFκB have been
observed in tumors [7]. NFκB is activated in response to
various inflammatory stimuli including cytokines, mito-
gens, bacterial products, viral proteins, and apoptosis-
i nducing  a ge n ts [8, 9] . C on st it ut i ve e x pr es s ion of  NF κB
leads to activation of several factors involved in cell cycle
progression and cell differentiation for cancer metastasis.
Inhibition of NFκB activity in tumor cells dramatically
reduces cell growth in vitro and in vivo [10]. NFκB, possi-
bly through the activation of the antiapoptotic genes,
plays a key role in the protection of cells against inducers
of apoptosis including chemotherapeutic drugs [11]. Sev-
eral mechanisms including increased expression of NFκB
proteins, mutations and/or deletions in IκBα gene, and
increased IκBα turnover, are involved in NFκB hyperacti-
vation in tumor cells [7,12]. As such, various therapeutic
strategies aim to decrease chronic NFκB hyperactivation
by pharmacological as well as phytomedicinal approaches
in cancer [13-17]. NFκB-regulated genes are involved in
cell death, invasiveness, proliferation, angiogenesis,
inflammation and multidrug resistance (MDR). One of
the most important mechanisms by which tumor cells
resist to cytotoxic effects of a variety of chemotherapeutic
drugs (including vinblastine, doxorubicine, etoposide and
teniposide, as well as many other cytotoxic agents) is
overexpression of the mdr1 gene and its product, P-gly-
coprotein (P-gp) [18].
P-gp is a 180 kDa protein which belongs to the ATP-
binding cassette (ABC) superfamily of membrane trans-
porter proteins [19,20]. It is expressed in various tissues,
s u c h  a s  k i d n e y  t u b u l e s ,  c o l o n ,  p a n c r e a s  a n d  a d r e n a l
gland, and tumors derived from these tissues are often
resistant to chemotherapeutic drugs. Furthermore, mdr1
expression is also increased in many relapsing cancers. P-
gp is an energy-dependent drug efflux pump that main-
tains intracellular drug concentrations below cytotoxic
levels, thereby decreasing the cytotoxic effects of a variety
of chemotherapeutic agents, including anthracyclines,
vinca alkaloids, and epipodophyllotoxins [18,21]. P-gp
also plays a role in inhibition of drug accumulation and
caspase activation in the MDR tumor [22-24]. Of special
note, NFκB-mediated drug resistance was found to
depend on the regulation of P-gp [25]. In addition, NFκB-
dependent regulation of P-gp expression has also been
demonstrated in renal tubules or liver [26,27]. By upregu-
lation of P-gp expression, NFκB was found to control
drug efflux in cancer cells.
Cancer cells contain multiple signal transduction path-
ways whose activities are frequently increased due to cell
transformation, and these pathways are often activated
following cell exposure to established cytotoxic therapies,
including ionizing radiation and chemical DNA-damag-
ing agents. Many pathways activated in response to trans-
formation or cytotoxic agents promote cell growth and
invasion, which counteract the processes of cell death. As
a result of these findings, many drugs with varying speci-
ficities have been developed to block the signaling by
these cell survival pathways in the hope of killing tumor
cells and sensitizing them to toxic therapies [28]. Unfor-
tunately, due to the plasticity of signaling processes
within a tumor cell, inhibition of a single growth factor
receptor or signaling pathway frequently has only modest
long-term effects on cancer cell viability, tumor growth,
and patient survival. As a result of this observation, a
greater emphasis has begun to be put on multi-target nat-
ural compounds, such as polyphenols, withanolides, xan-
thones, indanones, curcuminoids, which simultaneously
inhibit multiple inter-linked signal transduction/survival
pathways [14,28-33]. Hopefully, this could limit the ability
of tumor cells to adapt and survive, because the activity
within multiple parallel survival signaling pathways has
been reduced [34]. As such, over the past decades, the
efforts of researchers in looking for the new drugs to use
in oncology have refocused on natural products [1,34].
One of the expanding directions of modern medicine is
based on using of natural phytochemical compounds.
Polyphenols or phenolic compounds encompass mole-
cules that possess an aromatic ring bearing one or more
hydroxyl substituents. Natural polyphenols can range
from simple molecules, such as phenolic acids and fla-
vonoids, to large highly polymerized compounds, such as
tannins [35]. This class of phytochemicals can be found in
high concentrations in wide varieties of higher plants and
t h e i r  p r o d u c t s ,  s u c h  a s  w i n e  a n d  t e a .  T h e y  w e r e  a l s o
demonstrated to exert a wide range of biological activities
including antioxidant, anticarcinogenic, antiproliferative,
antimicrobial anti-inflammatory and apoptosis-inducing
activities [36-40].
Various polyphenols have been characterized with
respect to their anti-invasive potential. Because invasion
is, either directly or via metastasis formation, the main
cause of death in cancer patients, development of effi-
cient anti-invasive agents is an important research chal-
lenge [31]. Vanden Berghe et al. showed that
phytoestrogenic soy isoflavones can selectively block
nuclear NFκB transactivation of specific NFκB target
genes independently of their estrogenic activity in highly
metastatic breast cancer cells [16]. In 12-O-tetrade-
canoylphorbol-13-acetate (TPA)-induced mouse skinSuttana et al. Molecular Cancer 2010, 9:99
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tumor, the oligomeric and polymeric polyphenols
decreased TPA-induced cell proliferation by attenuating
the activation of signaling kinases [c-Jun N-terminal pro-
tein kinase (JNK), extracellular signal-regulated protein
kinase-1/2 (ERK1/2), p38 protein kinase and Akt], tran-
scription factors [activator protein-1 (AP1) and NFκB]
and inflammatory protein [cyclooxygenase-2 (Cox-2)]
[41,42]. The NFκB and Akt kinase pathways, which play
critical roles in inflammation, vascular homeostasis and
angiogenesis, were repressed by the polyphenolic com-
pound deguelin in human vascular endothelial cells,
HT1080 fibrosarcoma cells and chronic lymphocytic leu-
kemia cells [43-45]. Nitric oxide production was reduced
by the green tea polyphenols (-)-Epigallocatechin-3-gal-
late (EGCG) and black tea theaflavins by suppressing
inducible nitric oxide synthase in a breast cancer cell line
[46]. The latter treatment blocks nuclear translocation of
the transcription factor NFκB as a result of decreased IκB
kinase activity. However, anti-cancer effects of polyphe-
nols may also indirectly also involve effects on immune
cells at the cancer-inflammation interface. Several studies
demonstrated that polyphenolic compounds exhibit anti-
inflammatory activity in activated macrophages by inhib-
iting the NFκB signaling pathway [39,47,48]. Dijsselbloem
et al. demonstrated that genistein inhibits IL6 gene
expression by modulating the transcription factor NFκB
in TLR4-stimulated dendritic cells [49]. Pycnogenol
inhibits TNFα-induced NFκB activation and adhesion
molecule expression in human vascular endothelial cells
[50]. Red wine polyphenols, delphinidin and cyanidin
inhibit platelet-derived growth factorAB  (PDGFAB)-
induced VEGF release in vascular smooth muscle cells by
preventing activation of p38 MAPK and JNK [51]. Olive
oil polyphenols exert rapid inhibition of p38 and CREB
phosphorylation leading to a downstream reduction in
COX-2 expression in human colonic adenocarcinoma,
Caco-2 cells [52].
Previously, we have already reported the significant
anti-cancer activities of quercetin, Siamois 1 and Siamois
2 polyphenols and the withasteroid withaferin A, which
hold promise as dietary supplements in nutrition-based
intervention in cancer treatment [32,53]. In this study we
wanted to further investigate whether interference of Sia-
mois polyphenols and withasteroids with NFκB-depen-
dent apoptosis and inflammatory pathways can sensitize
doxorubicin-resistant P-gp-overexpressing K562 erythro-
leukemic cells for cell death.
Materials and methods
Reagents and Chemicals
Quercetin, Kaempferol, and Eriodictyol were from Extra-
synthèse (Genay, France), Withaferin A from Chromadex
(Irvine, US), whereas home-purified 5,3'-dihydroxy-
3,6,7,8,4'-pentamethoxyflavone (WP283) has been
described elsewhere [54]. These compounds were stored
as 100 mM solutions in DMSO at -20°C. Doxorubicin
hydrochloride was kindly provided by Dr. F. Offner (Uni-
versity Hospital UGent). Phorbol-12-myristate-13-ace-
tate (PMA) was purchased from Sigma Chemical
Company (St Louis, MO, USA) and stored as 1 mg/ml
solution in DMSO at -20°C. Recombinant murine TNF,
produced in Escherichia coli and purified in our labora-
tory to at least 99% homogeneity, had a specific biological
activity of 8.58 × 107 IU/ml of protein as determined in a
standard TNF cytolysis assay. Reference TNF (code 88/
532) was obtained from the National Institute of Biologi-
cal Standards and Control (Potters Bar, UK). Anti-IκBα,
anti-p65 (C20), anti-p50 (NLS), anti-cRel (N), anti-RelB
(C19), anti-Fra1(H50), anti-Nrf2 (C10), anti-Bax antibod-
ies were from Santa Cruz Biotechnology (Santa Cruz,
CA), anti-p38, anti-p44/42, anti-cfos, anti-cjun, anti-
junB, anti-junD from Active Motif, anti-Sirt1 from
Biomol, anti-Stat3 from Upstate, anti-histone-H3 anti-
bodies from Abcam and anti-tubulin were from Sigma
(Bornem, Belgium). The phospho-specific antibodies
directed against p65 Ser536, p38 and p44/42 MAPK,
cjun, Akt, MEK were from Cell Signaling (Beverly, CA).
Anti-Bcl-2, anti-Bim, anti-Bad, anti-P-Bad antibodies
were purchased from Cell Signaling (Boston, MA).
Cell culture and Cytotoxicity assay
M u r i n e  f i b r o s a r c o m a  L 9 2 9 s A  c e l l s  w e r e  m a i n t a i n e d  i n
Dulbecco's modified Eagle's medium supplemented with
5% newborn calf serum, 5% fetal calf serum, 100 units/ml
penicillin, and 0.1 mg/ml streptomycin. Twenty-four
hours before induction, cells were seeded in multiwell
dishes such that they were confluent at the time of the
experiment.
Doxorubicin-sensitive erythroleukemic cells (K562)
and doxorubicin-resistant erythroleukemic cells (K562/
Adr) which overexpress P-gp were grown in RPMI 1640
medium supplemented with 10% fetal calf serum, 100
units/ml penicillin, and 0.1 mg/ml streptomycin, in an
incubator at 37°C, 95% humidified, 5% CO2. Cultures ini-
tiated at a density of 105cells/ml grew exponentially to
about 106 cells/ml in 3 days. K562/Adr cell line was cul-
tured in RPMI 1640 medium in the presence of 100 nM
doxorubicin for 72 h, after that the cells were grown in
RPMI 1640 medium without doxorubicin for 2 weeks
before the experiments. For the assays and in order to
have cells in the exponential growth phase, cultures were
initiated at 5 × 105 cells/ml and used 24 h later, reaching a
density of about 8-10 × 105 cells/ml.
The cytotoxicity assay was performed as described pre-
viously [55]. Cells (5 × 104 cells/ml) were incubated in the
presence of various concentrations of compounds tested.
The viability of cells was determined by MTT reduction.
The concentration of compound required for 50% inhibi-Suttana et al. Molecular Cancer 2010, 9:99
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tion of the proliferation of cells (IC50) was determined by
plotting the percentage of cell growth inhibition (%IC)
versus the compound concentration when measured at
72 h. Alternatively, cell cytotoxicity assays were per-
formed by the ToxiLight Assay (Lonza) according to man-
ufacturer's instructions.
Apoptosis assay
Cells were washed with ice-cold phosphate-buffered
saline (PBS) after treatment, and 5 × 105  cells were
stained with annexin V (AnnV)-FITC during 15 min in
the dark followed by propidium iodide (PI) staining
(human AnnexinV-FITC Detection kit, Bender MedSys-
tems Diagnostics, Vienna, Austria). The stained cells (104
cells) were measured by flow cytometry (Cytomics FC500
1 laser, Beckman Coulter, Fullerton, USA) and results
were expressed as percentage of living (AnnV-, PI-), early
apoptotic (AnnV+, PI-), and late apoptotic/dead cells
(AnnV+, PI+). The percent of living cells was normalized
to 100% living cells incubated in control medium with
0.1% DMSO. All measurements were made in duplicate
and averaged.
IL6 ELISA
IL6 cytokine levels in cell-free culture supernatants were
determined using Hu-IL6 Cytoset ELISA kit (Biosource
International Inc. Camarillo USA) with detection limits
of 15 pg/ml, according to the manufacturer's instructions.
Three independent experiments were done, each in trip-
licate.
Measurement of caspase-3/7 activity
After appropriate induction, cells were washed with ice-
cold PBS and the cytosolic cell lysate was prepared as
described previously [56]. Measurement of caspase-3/7
activity was carried out by the incubation of cytosolic cell
lysate with fluorogenic substrates, Ac-DEVD-AMC. The
release of fluorescent AMC was monitored for 1 h at 37°C
at 2-min time intervals in a fluorescence microplate
reader (Packard Instrument Co.) using a filter with an
excitation wavelength of 360 nm and a filter with an emis-
sion wavelength of 460 nm [57,58]. Data are expressed as
t h e  i n c r e a s e  i n  f l u o r e s c e n c e  a s  a  f u n c t i o n  o f  t i m e
(Δfluorescence/min) normalized with that of cells incu-
bated in control medium with 0.1% DMSO.
Reporter Gene Analysis
The recombinant plasmid p(IL6κB)350 hu.IL6P-luc+ was
described previously [59,60]. Stable transfection of
L929sA cells was performed by the calcium phosphate
precipitation procedure according to standard protocols
[59]. Luciferase and galactosidase reporter assays were
carried out according to the manufacturer's instructions
(Promega) and have been described previously [59]. Nor-
malization of luciferase activity was performed by mea-
surement of β-galactosidase levels in a chemiluminescent
reporter assay Galacto-Light kit (Tropix, Bedford, MA).
Light emission was measured in a luminescence
microplate reader (Packard Instrument Co.). Luciferase
activity, expressed in arbitrary light units, was corrected
for the protein concentration in the sample by normaliza-
tion to the co-expressed β-galactosidase levels. β-Galac-
t o s i d a s e  p r o t e i n  l e v e l s  w e r e  q u a n t i f i e d  w i t h  a
chemiluminescent reporter assay Galacto-Light kit
(Tropix).
Western blot analysis
For the western blot analysis of total cell lysates, cells
were washed with ice-cold PBS before lysis in catenine
lysis buffer (1% Triton X-100, 1% NP-40, 10 mg/l leupep-
tine, 10 mg/l aprotinin, 2 mM PMSF, 10 mM sodium fluo-
ride, 10 mM sodium pyrophosphate, 1 mM sodium
vanadate). Protein concentration in lysates was measured
using BCA™ Protein Assay Kit (Thermo Scientific, Rock-
ford, USA) according to the manufacturer instructions.
Lysates were stored at -20°C until assayed.
Before analysis, lysates were diluted to reach equal pro-
tein concentration in each sample, and SDS sample buffer
was added (0.5 mM Tris-HCl, pH 6.8, 40% glycerol, 9.2%
SDS, 5% mercaptoethanol, and 0.05% w/v bromophenol
blue), one part of buffer for three parts of diluted lysate.
To shear DNA and reduce sample viscosity, samples were
heated to 95°C for 5 min, after which they were immedi-
ately cooled on ice and microcentrifuged for 5 min. For
the western blot analysis of nuclear extract, the nuclear
proteins were suspended in SDS sample buffer at the
same concentration. The protein samples were separated
by 12% SDS-PAGE and electrotransferred onto a nitrocel-
lulose membrane. Blots were probed using the appropri-
ate antibodies and the immunoreactive protein was
detected using enhanced chemiluminescence reagents on
an Odyssey imaging system (LI-COR Biosciences, Lin-
coln, USA).
Electrophoretic Mobility Shift Assay (EMSA)
After treatment, cells were washed with ice-cold PBS and
pelleted in 1 ml PBS by centrifugation for 10 min at 2600
rpm (4°C). Preparation of nuclear extracts has been
described previously [60]. For EMSA, equal amounts of
protein were incubated for 25 min with an NFκB-specific
32P-labeled oligonucleotide and binding mix as described
previously [32]. For supershift assay, antibodies were pre-
incubated to the sample of interest for 10 minutes prior
to incubation with radiolabeled probe [61]. Labeling of
the oligonucleotides was performed with [α-32P]-dCTP
by using Klenow enzyme (Boehringer Mannheim). For
EMSA competition assays, 100 fold excess of unlabeled
NFκB oligonucleotide was added to the binding mix. The
NFκB oligonucleotide comprises the sequence: 5'-AGC-Suttana et al. Molecular Cancer 2010, 9:99
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TATGTGGGTTTTCCCATGAGC-3', in which the single
IL6 promoter-derived NFκB motif is bold and italicized.
Samples were loaded on a 6% polyacrylamide gel run in
0.5 × TBE buffer (pH 8) and complexes formed were ana-
lyzed using Phosphor Imager Technology.
RNA isolation and real-time Q-PCR analysis
Total RNA was extracted with the acid guanidinium thio-
cyanate-phenol-chloroform method using the Trizol
reagent (Invitrogen, Merelbeke, Belgium). Reverse tran-
scription was performed on 500 ng of total RNA in a 30 μl
total volume. For normalization, cDNA concentrations in
each sample were determined prior to quantitative real-
time PCR (Q-RT-PCR). The Q-RT-PCR was performed
o n 5 μl  of  ea c h c o ndit ion usi ng In vit r oge n S ybr  gr ee n
platinum Supermix-UDG on a iCycler apparatus (Bio-
Rad, Eke, Belgium). All amplifications were performed in
duplicate or triplicate, and data were analyzedanalyzed
using Genex software (Bio-Rad, Eke, Belgium). Data were
expressed as mRNA expression normalized with that of
cells incubated in control medium with 0.1% DMSO. Q-
PCR primers are summarized in Table 1.
Results
Siamois polyphenols and the withasteroid withaferin A 
dose dependently inhibit NFκB-driven reporter gene 
expression
As anti-cancer properties of various polyphenols have
been linked to inhibition of the inflammatory transcrip-
tion factor NFκB, we first compared potential anti-
inflammatory properties of the Siamois polyphenols
quercetin, kaempferol, eriodictyol, WP283 and the with-
asteroid withaferin A (Fig. 1A) in NFκB-driven reporter
gene assays. First, we performed a dose response experi-
ment on L929sA cells, stably transfected with a TNF-
inducible NFκB-driven reporter gene construct with a
minimal IL6 promoter (p(IL6κB)3-50 hu.IL6P-luc+) and a
constitutively expressed reporter gene construct
(pPGκBGeobpA) controlled by the phosphoglyceroki-
nase promoter [60] for normalization of reporter gene
expression. Upon TNF treatment, significant promoter
induction can be observed with the NFκB-driven
reporter gene construct, which can be reversed with
quercetin, kaempferol, eriodictyol, WP283 or withaferin
A in a dose-dependent manner. IC50 values for NFκB
inhibition for the different Siamois polyphenols vary in
the concentration range of 30 to 50 μM and 0.5-1 μM for
withaferin A (Fig. 1B).
Siamois polyphenols and withaferin A inhibit endogenous 
NFκB target gene transcription in K562 and K562/Adr cells, 
irrespective of doxorubicin sensitivity
To validate our reporter gene expression results in more
specific cancer settings, we further studied Siamois poly-
phenol effects in K562 and K562/Adr cells, which may
demonstrate different NFκB activation status related to
doxorubicin sensitivity [62]. Since NFκB hyperactivation
is involved in chemoresistance, we next evaluated
whether different types of NFκB inhibitors may have dif-
ferent effects on endogenous NFκB target genes in K562
and K562/Adr cells, involved in inflammation, metastasis
(IL6, IL8, MCP1, A20), cell cycle (cyclin D1), angiogene-
sis (VEGF), multidrug resistance (mdr1/P-gp), and apop-
tosis (A1/Bfl1). Cells were pretreated with Siamois
polyphenols or withaferin A for 2 h, either or not follow-
ing 3 h treatment of PMA, after which RNA was isolated
and mRNA levels of interest were quantified by Q-PCR
with specific primers. As illustrated in Fig. 2, NFκB target
genes are potently induced by PMA in both cell types.
Surprisingly, NFκB target genes are differentially
expressed in K562 as compared to K562/Adr cells. More
particularly, whereas IL6, IL8, MCP1 and A1/Bfl1 reveal
stronger transcription in K562 cells, A20, cyclin D1,
VEGF and P-gp, are preferentially expressed in K562/Adr
cells. Furthermore, repression of PMA-inducible NFκB
target genes can be observed in K562 and K562/Adr cells,
irrespective of levels of Mdr1/P-gp expression. Interest-
Table 1: Primers sequences used in the real-time Q-PCR. 
Note: the abbreviations used in the table: FW indicates 
forward; REV, reverse.
IL6 FW GACAGCCACTCACCTCTTCA
IL6 REV AGTGCCTCTTTGCTGCTTTC
IL8 FW GCTCTCTTGGCAGCCTTCCTGA
IL8 REV ACAATAATTTCTGTGTTGGCGC
A/BFL-1 FW GATTTCATATTTTGTTGCGGAGTTC
A/BFL-1 REV TTTCTGGTCAACAGTATTGCTTCAG
MCP1 FW ACTCTCGCCTCCAGCATG
MCP1 REV TTGATTGCATCTGGCTGAGC
A20 FW CCTTGCTTTGAGTCAGGCTGT
A20 REV TAAGGAGAAGCACGAAACATCGA
CYCLIND1 FW CGCCCCACCCCTCCAG
CYCLIND1 REV CCGCCCAGACCCTCAGACT
VEGF FW GCCTCCCTCAGGGTTTCG
VEGF REV GCGGCAGCGTGGTTTC
MDR1 FW CTGCTTGATGGCAAAGAAATAAAG
MDR1 REV GGCTGTTGTCTCCATAGGCAATSuttana et al. Molecular Cancer 2010, 9:99
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ingly, although NFκB inhibitors can completely reverse
the effect of PMA on P-gp expression in K562/Adr cells,
its basal transcription levels cannot be further reversed to
the background P-gp levels as observed in K562 cells.
Finally, efficacy of target gene repression seems also to
be compound- and target gene-specific. Altogether, these
results demonstrate differential inhibitory effects of Sia-
mois polyphenols and withasteroids on target genes
Figure 1 Siamois polyphenols and withasteroids dose-dependently inhibit NFκB-dependent reporter gene expression. A) Chemical formu-
las of quercetin, kaempferol, eriodictyol, WP283, and withaferin A. B) L929sA cells, stably transfected with p(IL6κB)350 hu.IL6P-luc+, were left untreated 
or were pretreated with a concentration range of 100-50-25-12.5 μM Siamois polyphenol (quercetin, kaempferol, eriodictyol, WP283) or 3-1.5-0.75-
0.38 μM withaferin A for 2 h, and then stimulated with 2000 IU/ml TNF for 4 h. NFκB-dependent reporter gene expression was normalized for PGK 
housekeeping reporter gene expression. Data of two independent experiments, each done in triplicate, are presented as mean ± S.E.M.Suttana et al. Molecular Cancer 2010, 9:99
http://www.molecular-cancer.com/content/9/1/99
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Figure 2 Siamois polyphenols and withasteroids inhibit endogenous NFκB-dependent transcription in K562 and K562/Adr cells. K562 and 
K562/Adr cells were pretreated with 100 μM of quercetin, kaempferol, eriodictyol, WP283, or 6 μM of withaferin A for 2 h followed by incubation with 
PMA (0.1 μg/ml) for 3 h. Total RNA was isolated and mRNA was converted into cDNA. Relative mRNA levels were quantified by QPCR by specific primer 
sets for A) IL6, IL8, A1/Bfl1, MCP1, B) A20, cyclin D1, VEGF, mdr1. Specific mRNA transcription levels were normalized by transcription levels of cells 
incubated in control medium with 0.1% DMSO. Data of two independent experiments, each done in triplicate, are presented as mean ± S.E.M.
A
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involved in inflammation, metastasis, cell cycle, angio-
genesis, multidrug resistance, and anti-apoptosis in doxo-
rubicin-sensitive or -resistant K562 cells.
Siamois polyphenols and withaferin A inhibit endogenous 
IL6 protein expression in K562 and K562/Adr cells, 
irrespective of doxorubicin sensitivity
To evaluate whether inhibition of endogenous NFκB tar-
get genes is also translated at the protein level, we per-
formed IL6 ELISA of IL6 protein secreted into the
medium of K562 and K562/Adr cells, pretreated with dif-
ferent doses of quercetin or withaferin A for 3 h, either or
not following 15 h treatment of PMA, after which
medium was collected to determine IL6 protein levels. As
illustrated in Fig. 3, a comparable dose dependent
decrease in IL6 protein levels can be observed in both cell
types. In line with the NFκB reporter gene results, inhibi-
tion of IL6 protein expression can be achieved with lower
concentrations withaferin A than quercetin.
All the Siamois polyphenols and withaferin A prevent IκB 
degradation but the compounds selectively interfere with 
p38, ERK MAPK, MEK1 and Akt kinase activation
As NFκB target gene expression encompasses multiple
regulatory steps, including IκB degradation, NFκB trans-
location, NFκB/DNA binding and NFκB transactivation,
we next aimed to dissect which regulatory steps are
affected by Siamois polyphenols in K562 and K562/Adr
cells. Since IκBα degradation is required for liberation
and subsequent translocation of NFκB to the nucleus, we
determined Siamois polyphenol effects on PMA-induced
IκBα protein degradation in K562 and K562/Adr cells. As
maximal degradation of IκBα is observed between 15-30
minutes after PMA treatment (data not shown), we next
measured effects of Siamois polyphenols and withaferin
A on IκB degradation following 2 h pretreatment and 30
minutes cotreatment with PMA. From Fig. 4A, it can be
observed that all tested compounds reduce IκB degrada-
tion in both cell types. Along the same line, all tested
compounds significantly reduce basal and/or PMA-
inducible p65 Ser536 phosphorylation in both cell types.
Altogether, these results suggest that activation of NFκB
and subsequent translocation of NFκB for gene induction
is significantly reduced in presence of Siamois polyphe-
nols and the withasteroid withaferin A.
As target gene-specific effects are also depending on
p65 phosphorylation status and epigenetic settings,
dynamically controlled by multiple kinase pathways, i.e.
Akt, MAPK, MSK, PKA, we next measured P-Akt, P-p38,
P-ERK levels in the various experimental conditions in
both cell types. A significant reduction of basal and
PMA-induced P-Akt and P-p38 levels can be observed
upon treatment with quercetin and kaempferol, but not
with withaferin A in both K562 cell types (Fig. 4A),
whereas P-ERK levels do not reveal significant inhibition
(Fig. 4B). In contrast weak ERK stimulation could rather
be observed with withaferin A and quercetin (Fig. 4B).
Western analysis against p38 and ERK protein levels con-
firms equal protein loading in the various experimental
setups (Fig. 4A). Interestingly, Siamois polyphenols and
withaferin A demonstrate increased MEK1-phosphoryla-
tion in K562/Adr cells, suggesting that uptake of com-
pounds is not impaired in P-gp-overexpressing K562/Adr
cells.
Altogether, besides significant inhibition of IκB degra-
dation and NFκB p65 Ser536 phosphorylation by Siamois
polyphenols and withaferin A, compound-specific regu-
lation of p38, ERK, Akt and MEK kinases could be
observed, which may further interfere with nuclear tran-
scriptional regulation of NFκB target genes [63-65].
K562 and K562/Adr cells reveal distinct nuclear regulation 
of NFκB, AP1, Nrf2 and Sirt1 proteins
As K562 and K562/Adr demonstrate differential regula-
tion of NFκB target genes, we next explored whether both
cell types may show different nuclear regulation of poten-
tial cooperative transcription factors (i.e. AP1, Nrf2) or
cofactors (Sirt1) which might coregulate NFκB target
g e n es.  As  ca n  be  o bse rv ed  f r o m  F i g.  5 ,  bas a l  l ev e l s  o f
nuclear NFκB p65, AP1 c-Jun, JunD and Fra1 are signifi-
cantly increased in K562/Adr cells, but not of cRel and
RelB. This confirms previous observations on doxorubi-
cin-resistant MCF7 cells, in which AP1 transcription fac-
tors were demonstrated to be responsible for
upregulation of P-gp/Mdr1 [66]. Furthermore, PMA
treatment significantly increases nuclear levels of NFκB
p65, RelB, c-Rel. Of special note, increased nuclear levels
of Nrf2 upon PMA treatment are more pronounced in
K562/Adr than in K562 cells. Only recently, involvement
of Nrf2 has been demonstrated in chemoresistance [67].
Also in line with previous studies on the role of Sirt1 in
chemoresistance, basal Sirt1 levels are slightly increased
in doxorubicin-resistant K562/Adr cells. More particu-
l a r l y ,  S i rt 1  was  f o u n d  t o  pos i t i v e l y  c o n t ri b u t e  i n  P - gp /
Mdr1 expression [68]. Altogether, our results demon-
strate that activities of NFκB p65, AP1 cjun, junD, Fra1,
Nrf2 transcription factors and Sirt1 cofactors are
increased in doxorubicin-resistant K562/Adr cells.
NFκB, AP1 DNA-binding profiles in K562 and K562/Adr cells 
show qualitative and quantitative differences
To compare DNA-binding properties of NFκB and AP1 in
K562 and K562/Adr cells, we performed electrophoretic
gel shift mobility assays (EMSA) and supershift analysis
in response to PMA stimulation. Fig. 6A reveals that both
cell types show inducible NFκB/DNA binding, whereas
basal NFκB/DNA binding is slightly elevated in doxorubi-
cin-resistant K562/Adr cells, in line with observationsSuttana et al. Molecular Cancer 2010, 9:99
http://www.molecular-cancer.com/content/9/1/99
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that doxorubicin can elevate basal NFκB activation via
DNA damage pathways [69]. Also, K562 and K562/Adr
cells show different composition of NFκB/DNA binding
complexes. Interestingly, despite increased levels of
NFκB/DNA binding observed in K562/Adr cells, it has
been demonstrated that NFκB phosphorylation/acetyla-
tion levels are reduced, which affects its transcriptional
properties for specific subsets of NFκB target genes
[70,71]. Along the same line, supershift analysis reveals
subtle differences in the heterodimer/homodimer com-
position of DNA-bound NFκB and AP1-binding com-
plexes in both cell types. Supershift analysis reveals at
least three different NFκB/DNA-binding complexes
including p65-p65, p50-p65, and p50-p50. In K562/Adr
cells, basal NFκB/DNA binding of the p50-p65 complex
appears to be increased relative to K562 cells. Similarly,
increased basal and inducible AP1 binding is detected in
K562/Adr cells in comparison with K562 cells, in line
with increased levels of nuclear AP1 members. Further-
more, although both cell types demonstrate PMA induc-
Figure 3 Inhibitory effect of withaferin A and quercetin on IL-6 protein production in K562 and K562/Adr cells. K562 and K562/Adr cells were 
pretreated with quercetin or withaferin A in different concentrations (as indicated in Figure). for 3 h, followed by incubation with PMA (100 ng/ml) for 
15 h. Cell-free medium supernatant was collected for ELISA quantification of secreted levels of IL-6 protein. Data are presented as percent of control 
(zero concentration of withaferin A or quercetin), as mean ± S.E.M. of three independent experiments, each done in triplicate. Following IC50 values 
were obtained: 0.54 μM withaferin A and 29.5 μM quercetin for K562 cells; 0.58 μM withaferin A and 13.2 μM quercetin for K562/Adr cells.
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ible NFκB/DNA binding, K562 cells show higher
intensity of p65-p65 heterodimers but comparable
amounts of p50-p65 and p50-p50 DNA-binding com-
plexes in comparison to K562/Adr cells (Fig. 6A). Con-
cerning AP1-binding complexes, increased Fra1 levels
can be detected in K562/Adr cells as compared to K562
cells. EMSA competition with excess of unlabeled NFκB
or AP1 DNA-binding motifs further demonstrates speci-
ficity of the DNA-bound NFκB, RBP-Jκ and AP1-binding
complexes.
Siamois polyphenols quercetin, eriodictyol and withaferin 
A strongly inhibit DNA binding of NFκB, AP1 and Nrf2
To verify whether transcriptional repression of target
genes involved in inflammation, anti-apoptosis, angio-
genesis, metastasis, drug resistance by Siamois polyphe-
nols and withaferin A could be the consequence of
inhibition of NFκB, AP1 or Nrf2 TF/DNA binding in
K562 and K562/Adr cells, we performed EMSA experi-
ments with nuclear extracts from cells treated with PMA
alone, or following pretreatment with Siamois polyphe-
nols. As shown in Fig. 6B, basal constitutive p50-p50 and
Figure 4 Selective effects of Siamois polyphenols and withasteroids on the NFκB signaling pathway. K562 and K562/Adr cells were either or 
not pretreated with 100 μM of quercetin, kaempferol, eriodictyol, WP283 or 6 μM of withaferin A for 2 h followed by incubation with PMA (0.1 μg/ml) 
for 30 minutes. Total cell lysates were prepared in SDS-Laemmli sample buffer and extracts were analyzed for protein expression levels of A) IκB, p65, 
P-Ser536 p65, P-p38, P-Akt, tubulin, B) P-MEK1, P-ERK, ERK, respectively.Suttana et al. Molecular Cancer 2010, 9:99
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p50-p65 NFκB/DNA-binding activity in K562/Adr is
increased as compared to K562 cells. PMA stimulation
again increases p50-p50 and p50-p65 NFκB/DNA bind-
ing in both cell types whereas p65-p65 homodimers
demonstrate stronger DNA binding in K562 only. Fur-
thermore, treatment with different Siamois polyphenols
and withaferin A causes strong to moderate inhibition of
the basal and inducible p50/p65 NFκB/- and AP1/DNA-
binding complexes, as shown in Fig. 6B[61]. Along the
same line, Nrf2/DNA binding is increased in K562/Adr
cells as compared to K562 cells, whereas Siamois poly-
phenols and withaferin A are able to reduce basal and
PMA-inducible Nrf2 binding in both cell types [67,72].
Among the different Siamois polyphenols tested, querce-
tin and eriodictyol show the strongest inhibition of TF/
DNA binding, whereas kaempferol and WP283 are less
effective. Nevertheless, transcriptional inhibition of the
various target genes (Fig. 6B) by Siamois polyphenols and
withaferin A is regulated at multiple levels and depends
on DNA-binding properties of NFκB, AP1, Nrf2 tran-
scription factors, nuclear cofactor dynamics, as well as
epigenetic settings [64,71,73,74]. Of special note,
although Siamois polyphenols and withaferin A are able
to reverse inducible NFκB/DNA binding in K562/Adr
cells, constitutive NFκB/DNA-binding levels cannot be
further decreased to levels observed in K562 cells.
Siamois polyphenols and withaferin A reduce cell viability 
in both K562 and K562/Adr cells
K562 and K562/Adr cells which are sensitive or resistant
to doxorubicin, respectively, were incubated with doxoru-
bicin, withaferin A or Siamois polyphenols, including
quercetin, kaempferol, eriodictyol and WP283 to evaluate
cytostatic and/or cytotoxic activity of the various com-
pounds. After 72 h, cell survival was determined by the
MTT cell viability assay and the IC50 values are summa-
rized in Fig. 7A. Among Siamois polyphenols, WP283
and eriodictyol exhibit the strongest and weakest effects
in mitochondrial reduction of tetrazolium salts to forma-
zan. Of particular interest, K562 and K562/Adr cells
reveal comparable sensitivity to Siamois polyphenols and
withaferin A, whereas IC50 values for doxorubicin show a
20-fold higher sensitivity in sensitive K562 cells, as com-
pared to resistant K562/Adr cells. These results indicate a
pronounced cellular resistance for doxorubicin as com-
pared to Siamois polyphenols and withaferin A.
To exclude any potential artefacts that may come from
interaction of intracellular polyphenols with MTT, which
could be directly reduced by these compounds [75], we
have also measured cytotoxic effects of quercetin, witha-
ferin A and doxorubicin with a bioluminescent luciferase/
luciferin ATP based cytotoxicity assay (ToxiLight). In
accordance with MTT results, K562/Adr cells show cellu-
lar resistance to doxorubicin (Fig. 7B). Furthermore,
K562 cells show high sensitivity to both withaferin A and
quercetin, while K562/Adr cells show significantly
reduced sensitivity to quercetin, and their sensitivity to
withaferin A is only partially lost in comparison to K562
cells (Fig. 7C).
Withaferin A, but not Siamois polyphenols, induces 
execution of apoptosis
Next, K562 and K562/Adr cells were incubated for 48 h
with Siamois polyphenols or withaferin A, followed by
annexin V-FITC/PI double staining and FACS analysis to
quantify early annexin V-FITC positive) and late (annexin
V-FITC/PI double positive) apoptotic cells. The relative
percentage of apoptotic/living cells in the different exper-
imental setups in K562 and K562/Adr cells, following 48
h treatment are represented as a bar graph in Fig. 8. Inter-
Figure 5 K562 and K562/Adr cells reveal different nuclear regula-
tion of NFκB, AP1, Nrf2 transcription factors and Sirt1 cofactors. 
K562 and K562/Adr cells were treated with PMA (0.1 μg/ml) for 30 min-
utes. Nuclear cell lysates were prepared in SDS-Laemmli sample buffer 
and extracts were analyzed for protein expression levels by Western 
analysis of NFκB p65, RelB, cRel, Nrf2, AP1 cjun, junD, Fra1, Sirt1, respec-
tively. Comparable protein loading was verified with Histone H3 anti-
bodies.Suttana et al. Molecular Cancer 2010, 9:99
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estingly, although both cell types show comparable early
apoptotic cell populations in presence of the different Sia-
mois polyphenols, late apoptotic cells only accumulate in
K562 cells. In contrast to Siamois polyphenols, only
withaferin A is able to trigger late apoptosis in K562/Adr
cells. Furthermore, although the concentrations applied
of the different Siamois polyphenols closely relate to the
IC50 values determined in MTT assay (Fig. 8), FACS
Figure 6 K562 and K562/Adr cells show qualitative and quantitative differences in NFκB and AP1 DNA binding profiles. A) K562 and K562/
Adr cells were pretreated with PMA (0.1 μg/ml) for 30 minutes. Nuclear lysates were analyzed for NFκB/DNA and AP1/DNA binding with a radiolabeled 
IL6 κB site- or AP1 motif-containing probe. Binding complexes formed were analyzed by EMSA. Loading of equal amounts of protein was verified by 
comparison with the binding activity of the repressor molecule recombination signal sequence-binding protein Jκ (RBP-Jκ). Specificity of the various 
complexes bound is demonstrated by supershift analysis with NFκB- and AP1-specific antibodies, as well as by competition with 100-fold excess cold 
oligonucleotide. B) K562 and K562/Adr cells were pretreated with 100 μM of quercetin, kaempferol, eriodictyol, WP283, or 6 μM of withaferin A for 2 
h followed by incubation with PMA (0.1 μg/ml) for 30 minutes. Cell lysates were fractionated for cytoplasmic and nuclear extracts which were analyzed 
for NFκB, AP1, or Nrf2-dependent DNA binding with specific radiolabeled probes. Binding complexes formed were analyzed by EMSA.
A
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analysis (Fig. 8) reveals significant variation in apoptosis
efficacy between the different polyphenol compounds.
The latter suggests significant discrepancies between
MTT cell viability assays revealed by mitochondrial
reduction of tetrazolium salts and cell survival score mea-
sured by Annexin V/PI apoptosis FACS assay [75].
Indeed, it is of utmost importance to perform multiple,
methodologically unrelated assays to quantify dying and
dead cells [75,76].
Next, as apoptotic threshold in compound-treated
K562/Adr cells may be higher due to elevated basal anti-
apoptotic activity of NFκB, AP1 and Nrf2, we wanted to
further evaluate whether increasing activity of NFκB,
AP1 and Nrf2 by PMA treatment in K562 cells could sim-
Figure 7 Cytotoxic effects of Siamois polyphenols and withaferin A in K562 and K562/Adr cells. A) K562 and K562/Adr cells were treated with 
various concentrations of quercetin, kaempferol, eriodictyol, WP283 or withaferin A for 72 h. Cell survival was determined by mitochondrial MTT assay 
and IC50 values were determined for cytotoxicity of the different compounds. B) K562 and K562/Adr cells were treated with various concentrations 
doxorubicin for 48 h. % Cell cytotoxicity was determined by ToxiLight assay. C) K562 and K562/Adr cells were treated with various concentrations 
withaferin A or quercetin for 48 h. % Cell cytotoxicity was determined by ToxiLight assay.
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ilarly protect compound-treated K562 cells from late
apoptosis in analogy to K562/Adr cells. However,
although the relative number of late apoptotic cells
decreases upon cotreatment of K562 cells with PMA and
Siamois polyphenol inhibitors (Fig. 8), execution of apop-
tosis is not completely blocked because Siamois polyphe-
nols are able to partially counteract PMA effects on
NFκB, AP1 and Nrf2. Along the same line, Siamois poly-
phenols cannot overcome the late apoptosis block in
K562/Adr cells, despite efficient inhibition of NFκB, AP1
and Nrf2. This suggests that execution of apoptosis in
K562/Adr cells is only in part determined by transcrip-
tional activity of NFκB, AP1 and Nrf2. Remarkably,
although withaferin A, and quercetin both dose depend-
ently inhibit NFκB, AP1 and Nrf2 in K562/Adr cells, only
withaferin A is able to trigger late apoptosis and over-
come the apoptosis block in K562/Adr cells, indicating
that withaferin A may also affect other death-inducing
pathways/mechanisms.
Withaferin A and quercetin induce early and late caspase 
activation respectively
In addition to propidium iodide as a late apoptotic FACS
marker, we next measured biochemical activation of the
Figure 8 Apoptotic effects of Siamois polyphenols and withasteroids in K562 and K562/Adr cells. Determination of early (AnnexV+, PI-) and 
late (AnnexV+, PI+) apoptotic cells by flow cytometric evaluation (AnnexinV-FITC and PI staining) of mean normalized percentages of living K562 and 
K562/Adr cells, either left untreated or treated with 100 μM of quercetin, kaempferol, eriodictyol, WP283 or 6 μM of withaferin A, or cotreated with 
PMA (0.1 μg/ml) for 48 h. Data of two independent experiments, each done in duplicate, are presented as mean ± S.E.M.
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Figure 9 Caspase 3/7 activation by Siamois polyphenols and withaferin A in K562 and K562/Adr cells. A) K562 and K562/Adr cells were either 
left untreated or treated with 100 μM of quercetin (Q), kaempferol (K), eriodictyol (E), WP283 (WP) or 6 μM of withaferin A (WA) for 12 h. Caspase-3 
activity present in cell lysates was determined by a fluorescent in vitro assay upon incubation of cell lysate with Ac-DEVD-fmk substrate. B) K562 and 
K562/Adr cells were either left untreated or treated with 100 μM quercetin for 6, 12, 24, 36 or 48 h. Caspase-3 activity present in cell lysates was deter-
mined by a fluorescent in vitro assay upon incubation of cell lysate with Ac-DEVD-fmk substrate. C) Percentage of living cells, following treatment with 
withaferin A (10 μM) or quercetin (100 μM) in the presence or absence of ZVAD fmk (50 μM), inhibitor of caspases. In all conditions, except control, 
cells were cultivated in medium containing 1% DMSO. After 48 h of cultivation, % dead cells were stained by annexin V/propidiumiodide followed by 
flow cytometry measurement. % Living cells is obtained by subtracting % dead cells. Data of two independent experiments, each done in duplicate, 
are presented as mean ± S.E.M.
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executioner caspases-3/7 in K562 and K562/Adr cells
exposed to PMA, Siamois polyphenols and/or withaferin
A in a fluorescent caspase substrate assay. In this respect,
K562 and K562/Adr cells were treated for 12 h with
PMA, Siamois polyphenols and/or withaferin A, after
which caspase activity present in the cell lysates was mea-
sured in presence of the caspase substrate Ac-DEVD-
fmk, which elicits fluorescence upon its cleavage. From
Fig. 9A it can be noticed that Siamois polyphenols
increase caspase-3/7 activity only in K562, but not in
K562/Adr cells, which is in good accordance with lack of
late apoptosis observed in K562/Adr cells. In contrast to
Siamois polyphenols, withaferin A is able to trigger cas-
pase-3/7 activity in both cell types Fig. 9A. Interestingly,Suttana et al. Molecular Cancer 2010, 9:99
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upon evaluation of quercetin-dependent activation of
caspase-3/7 at later time points, i.e. 36 h and 48 h, we
observed a delayed but significant increase in caspase-3/7
activity, which could be responsible for attenuation of late
apoptosis events in K562/Adr cells exposed to quercetin
(Fig. 9B). Kinetic differences in apoptosis by withaferin A
and quercetin will be further discussed in paragraphs
below. Further support for involvement of caspases in
withaferin A- and quercetin-dependent cell death in
K562 and K562/Adr cells follows from experiments in
presence of the pan-caspase inhibitor ZVAD-fmk. Briefly,
K562 and K562/Adr cells were grown for 48 h in witha-
ferin or quercetin in presence or absence of ZVAD-fmk.
As can be observed from Fig. 9C, withaferin A and quer-
cetin both trigger cell death in K562 cells which can par-
tially be reversed with the pan-caspase inhibitor ZVAD-
fmk. Also in K562/Adr cells, withaferin-dependent apop-
tosis effects can be partially reversed with ZVAD-fmk,
whereas ZVAD-fmk effects on the quercetin-dependent
apoptosis setup are much weaker, since quercetin
induced caspase-3/7 activation is less efficient or slower
than for withaferin treatment.
PARP cleavage by withaferin A in K562 and K562/Adr cells is 
reversible by thiol donors
Next, we further investigated by Western analysis
whether caspase activation results in cleavage of PARP,
caspase substrate and standard marker for apoptosis (Fig.
10). K562 and K562/Adr cells were incubated for 24 h
with different doses of withaferin A or quercetin. In line
with our FACS data and toxicity assays, high doses of
withaferin A trigger significant PARP cleavage in K562
cells and to a lesser extent in K562/Adr cells (Fig. 10A).
Also quercetin triggers PARP cleavage in K562 cells,
although in K562/Adr cells PARP cleavage is strongly
impaired or delayed. Since we and others previously dem-
onstrated reversal of biological effects of withaferin in
presence of excess amounts of thiol donors (i.e. mercap-
toethanol or dithiothreitol (DTT)) [32,77,78], we have
further tested whether PARP cleavage by withaferin A
could also be prevented in presence of DTT. Interestingly,
PARP cleavage by withaferin A in K562 and K562/Adr
cells was completely blocked following prior incubation
with DTT, illustrating a major role for thioalkylation tar-
gets in withaferin A-dependent cytotoxicity (Fig. 10B). In
contrast, quercetin effects on PARP cleavage could not be
attenuated by DTT in K562 cells.
Effect of withaferin A and quercetin on apoptosis-related 
proteins in K562 and K562/Adr cells
The Bcl2 family of antiapoptotic proteins (Bcl2, BclXL),
proapoptotic families of BH123 (Bax) and BH3 (Bim)
proteins represent 3 major classes of intracellular regula-
tors of apoptosis. As such, we performed Western analy-
sis to evaluate effects of withaferin A and quercetin on
Bcl2, BclXL, Bax and Bim protein levels in K562 and
K562/Adr cells, exposed for different time periods to high
or low concentrations of the compounds. In Fig. 11 we
demonstrate that in K562 cells, withaferin A and querce-
tin time-dependently and dose-dependently decrease the
levels of Bcl2, Bim and P-Bad protein, whereas BclXL and
Bax levels remain largely unaffected in any condition.
Similar results were obtained in K562/Adr cells, although
decrease of protein levels is generally delayed (starts to
appear at 24 h rather than 9 h). Furthermore, withaferin
A decreases protein levels of Bad whereas quercetin has
no effect. Finally and of special interest, in analogy to var-
ious anti-cancer drugs acting on the cytoskeleton and
interfering with tubulin dynamics, withaferin A seems to
significantly decrease tubulin protein levels, whereas no
effect can be observed in presence of quercetin.
Discussion
Extensive studies indicate that both hyperactivation of
NFκB and overexpression of multidrug transporters play
important roles in cancer chemoresistance
[7,18,25,27,62,68]. Since expression of the multidrug
transporter P-gp was found to be NFκB-dependent, it is
believed that NFκB inhibitors can decrease P-gp expres-
sion and restore chemosensitivity [1,14]. However, our
studies have shown that the picture is more complicated.
Previously, we have already demonstrated apoptosis of
MDA-MB435 cells in presence of Siamois polyphenols in
a xenograft model in vivo [53]. Furthermore, the NFκB
Figure 10 Differential efficacy of PARP cleavage by quercetin and 
withaferin A in K562 and K562/Adr cells. A) K562 and K562/Adr cells 
were either left untreated or treated with different doses of quercetin 
or withaferin A for 24 h. Cell lysates were analyzed for PARP cleavage 
by Western analysis. B) K562 and K562/Adr cells were either left un-
treated (1), 24 h treated with 100 μM of quercetin or 10 μM withaferin 
A (2), 24 h treated with 100 μM quercetin or 10 μM withaferin A follow-
ing 2 h prior WA preincubation with 1 mM DTT (3), or 24 h treatment 
with 1 mM DTT (4). Corresponding cell lysates were analyzed for PARP 
cleavage by Western analysis.Suttana et al. Molecular Cancer 2010, 9:99
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Figure 11 Effects of withaferin A and quercetin on intracellular apoptosis-related proteins in K562 and K562/Adr cells. K562 and K562/Adr 
cells were either left untreated or treated with different doses of quercetin or withaferin A for 6, 9 or 24 h. Equal protein amounts of corresponding 
cell lysates were analyzed for protein levels of Bcl2, BclXL, Bax, Bim, Bad, P-Bad and tubulin by Western analysis.
inhibitor withaferin A has been described as a promising
drug for cancer chemotherapy and radiosensitization
[32,79,80]. Now, we further analyzed whether withaferin
A or Siamois polyphenols quercetin, kaempferol, eriodic-
tyiol, and WP283 hold therapeutic promise as NFκB-
inhibitors for chemosensitization of doxorubicin resistant
K562/Adr erythromyelogenous leukemia cells. In NFκB
reporter gene studies, we compared dose-dependent
repression of luciferase gene expression in response to
Siamois polyphenols quercetin, kaempferol, eriodictyiol,
and WP283 with IC50 values in the range of 0.1-50 μM
respectively. Furthermore, upon comparing endogenousSuttana et al. Molecular Cancer 2010, 9:99
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gene transcription and protein expression of specific
NFκB target genes, we observed comparable potencies in
NFκB-dependent gene repression by Siamois polyphe-
nols in K562 and K562/Adr cell types. Of special note,
both cell types express different subsets of NFκB target
genes. More particularly, K562 cells reveal a predominant
inflammatory gene expression profile (i.e. strong expres-
sion of IL6, IL8, MCP1, and A1/Bfl1), whereas K562/Adr
cells demonstrate a more tumorigenic pattern (i.e. strong
expression of A20, cyclin D1, VEGF, and mdr1). As such,
we further studied NFκB signaling mechanisms and
coregulatory pathways which may be responsible for dif-
ferential NFκB target gene expression/inhibition and
apoptosis sensitivity for withaferin A and Siamois poly-
phenols. Upon characterization of the major NFκB acti-
vation and transactivation pathways, we found
differential regulation of NFκB activity by withaferin A
and quercetin, kaempferol, eriodictyol and WP283. Inter-
estingly, IκB degradation and NFκB/DNA binding was
significantly reduced by all compounds tested in both cell
types, among which withaferin A, quercetin and eriodic-
tyol showing the most potent inhibition, and kaempferol
and WP283 much weaker and variable inhibition.
Remarkably, increased levels of basal NFκB binding in
K562/Adr cells cannot be inhibited by Siamois polyphe-
nols in contrast to inhibition of inducible NFκB/DNA-
binding. Furthermore, relative composition of NFκB/
DNA binding complexes reveals that K562 cells contain
much higher levels of p65-p65 homodimers. Of particu-
lar interest, the inflammatory cytokine IL8 was found to
preferentially bind p65-p65 homodimers instead of p50-
p50 and p50-p65 dimers [81], which could explain strong
expression of inflammatory cytokines in K562 cells. From
another perspective, NFκB dimer composition may also
depend on the repertoire posttranslational modifications
present on NFκB [63,70,71,82,83]. More specifically, we
have detected variable and compound-specific effects on
p38 MAPK, MEK1, Akt kinase pathways, which may also
interfere with NFκB transcription factor composition
and/or activity. Finally, besides phosphoregulation of
transcription factors, acetylation by cofactors (CBP,
HDAC, Sirtuin) and DNA methylation have recently
added an additional epigenetic control of inducible NFκB
transcription [84-87]. Of special note, as doxorubicin was
found to increase Sirt1 HDAC levels [68], we compared
nuclear Sirt1 levels in both cell types and observed a sig-
nificant increase in Sirt1 protein in K562/Adr. As such,
we cannot exclude that in addition to kinases also Sirt
HDACs may contribute in cell-specific phosphoacetyla-
tion control of TF/DNA binding and transcriptional
activity and may prevent NFκB p65 homodimer forma-
tion. In addition to cell specific regulation of NFκB, it can
be observed from Fig. 5 that also AP1 members (i.e. Fra1,
cjun and junD) and Nrf2 are differentially expressed in
both cell types. As such, we can also neither exclude com-
pound-specific kinase effects on these transcription fac-
tor families, since various NFκB target genes involved in
inflammation, metastasis, angiogenesis and drug resis-
tance are also coregulated by AP1 and Nrf2 [66,67,88,89].
Most surprisingly, although inhibition of NFκB activity
in general contributes in chemosensitization of cancer
cells [5,62], caspase activation is delayed and apoptosis is
attenuated in K562/Adr cells treated with Siamois poly-
phenols, although efficacy of NFκB inhibition and initia-
tion of early apoptosis by Siamois polyphenols is similar
in doxorubicin-sensitive and resistant cell types. This is in
line with previous reports on drug resistance, which
d e s c r i b e  t h a t  P - g l y c o p r o t e i n  i n h i b i t s  c y t o c h r o m e  c
release and caspase-3/8 activation, but not formation of
the death-inducing signal complex [23,24,90]. Along the
same line, impaired activation of caspase 3,6,7,8,9,10 has
been described in doxorubicin-resistant breast cancer
cells [91]. The fact that Siamois polyphenols are able to
completely ablate NFκB target gene expression, hyperac-
tivate MEK1 and trigger early apoptosis in K562/Adr cells
argues against the hypothesis that Siamois polyphenols
may not be uptaken or are secreted out of the cell because
of hyperactivated P-gp activity in K562/Adr cells. As
such, P-gp overexpression confers resistance to a wide
range of caspase-dependent apoptotic agents not only by
removing drugs from the cell, but also by inhibiting the
activation of proteases involved in apoptotic signaling
[92]. Only a few drugs are reported to overcome this P-
gp/Mdr phenotype and most of them are molecules that
induce cell death in a caspase-independent manner [93].
Interestingly, in analogy to some specific glutathione S
transferase inhibitors (NBDHEX) and mitochondria-tar-
geting drugs (oligomycin) [94-96], withaferin A was
found to bypass the P-gp resistance and to overcome
attenuation of late apoptosis in K562/Adr cells. Unfortu-
nately, we could not detect major differences in regula-
tion of intracellular regulators of mitochondrial apoptosis
of the Bcl2, BH123 or BH3 family proteins in K562 and
K562/Adr cells treated with withaferin A or quercetin:
both treatments trigger time-dependent decrease of Bcl2,
Bim and P-Bad protein levels in K562 cells (albeit delayed
in K562/Adr cells). However, upon investigation of
cytoskeletal proteins, we observed that withaferin A is
able to decrease tubulin protein levels, whereas BclXL and
Bax protein levels remain unaffected. Interestingly, vari-
ous chemoresistant tumors, including doxorubicin resis-
tant cancers reveal therapy induced cytoskeletal changes
in microtubules and intermediate filaments [97,98]. In
analogy to other microtubule-targeted anti-cancer drugs,
withaferin A could restore therapy sensitivity in P-gp-
overexpressing cells by targeting the cytoskeletal organi-
zation. Further support for this mechanism has recently
been provided by other groups, describing involvementSuttana et al. Molecular Cancer 2010, 9:99
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of withaferin A-dependent actin and vimentin microfila-
ment aggregation in cancer cell apoptosis and suppres-
sion of angiogenesis via a direct thiol oxidation
mechanism [77,99,100]. Along the same line, we were
able to block withaferin A-induced effects upon competi-
tion with excess amounts of the cysteine donor molecule
DTT. Alternatively, it cannot be excluded that thiol-reac-
tivity of withaferin A interferes with cysteine-sensitive P-
gp protein folding steps and/or P-gp protein function
[101,102]. Further investigation is needed to map cysteine
target proteins of withaferin A which allow to bypass P-
gp chemoresistance and restore apoptosis sensitivity.
Conclusions
We found that transcriptional inhibition of NFκB-, AP1-
and Nrf2- driven target genes involved in inflammation,
metastasis, angiogenesis, drug resistance is not sufficient
to overcome the P-gp-coupled attenuation of caspase-
dependent apoptosis in K562/Adr cells. Remarkably, the
withanolide withaferin A was found to relieve attenuation
of caspase activation and apoptosis in K562/Adr cells,
presumably via a direct thiol oxidation mechanism which
targets cytoskeletal microfilaments, such as tubulin, actin
and vimentin. This makes withaferin A an attractive nat-
ural phytochemical compound to overcome drug resis-
tance and to elicit cell death in chemoresistant cell types.
However, Siamois polyphenols could also have therapeu-
tical benefit as well, upon suppression of cancer-promot-
ing inflammatory cytokines and growth factors involved
in cancer progression [103]. Furthermore, although less
effective in immediate eradication of apoptosis-deficient
tumor cells, chronic exposure to Siamois polyphenols
may demonstrate significant long-term anti-cancer prop-
erties upon epigenetic modulation of P-gp function and
cell survival [28,53,104-108]. The latter strategy may be
beneficial to globally retard progression of aggressive
refractory tumors, instead of chemotherapy of refractory
tumors, which may further select for clonal expansion
and evasion of chemoresistant and/or metastatic cancer
cells.
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